A review of the indications, safety, and efficacy of deucravacitinib: An expert consensus panel
Dermatology Online Journal · 09.05.2026 · 32 (2)
DOI: 10.25251/ymnfwz12 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Dermatology Online Journal, online erschienen am 09.05.2026. Verfasst von Milaan Shah und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Medical University of South Carolina, Charleston, SC. Hauptthemen laut MEDLINE: Psoriasis, TYK2 Kinase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Deucravacitinib is a novel, allosteric, selective TYK2 inhibitor FDA-approved for the treatment of moderate-to-severe plaque psoriasis in adults. Deucravacitinib is under investigation in numerous clinical trials to establish its efficacy and safety for other indications. Thus, this expert consensus panel was assembled to provide clinical guidance on the applications of and clinical considerations for deucravacitinib.
Methods
A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles regarding deucravacitinib. An expert panel of eight dermatologists reviewed the literature and developed consensus statements regarding the additional indications, safety, and efficacy of deucravacitinib. Using a modified Delphi process, each statement had supermajority approval and was designated a strength of recommendation based on the Strength of Recommendation Taxonomy criteria.
Results
The literature search resulted in 250 articles regarding deucravacitinib. 43 relevant articles were included and distributed to the panelists for review prior to the roundtable discussion. The panel unanimously voted to adopt 14 consensus statements and recommendations: 11 were a strength of “A”, 1 was a strength of “B”, and two were a strength of “C”.
Conclusion
Deucravacitinib is an established treatment for plaque psoriasis that has shown strong evidence supporting safety and efficacy for psoriatic arthritis, cutaneous lupus, and systemic lupus erythematosus. The 14 consensus statements created by the panel provide expert recommendations regarding the efficacy, safety, and additional potential indications for deucravacitinib. Additionally, the expert panel notes that deucravacitinib is generally safe, as it can be safely combined with conventional synthetic DMARDs, immunosuppressants, and biologics and currently does not have data that support elevated malignancy risk, tuberculosis reactivation, increased risk for herpes zoster, or associated laboratory abnormalities. The expert panel concludes that deucravacitinib is an exciting medication that will likely have a larger role in the treatment of various conditions in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Medical University of South Carolina, Charleston, SC.
- Department of Dermatology, University of Texas Southwestern, Dallas, TX.
- Department of Internal Medicine, University of Louisville School of Medicine, Louisville, KY.
- Department of Dermatology, University of Illinois Chicago, Chicago, IL.
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY.
- Department of Dermatology, University of California Los Angeles, Los Angeles, CA.
Zitieren
APA
Shah, M., DeBusk, L., Bohman, M. H., Rosenberg, A., Burshtein, J., Zakria, D., Armstrong, A., Boh, E., Gottlieb, A. B., Khattri, S., Litchman, G., Merola, J., Murina, A., & Lebwohl, M. (2026). A review of the indications, safety, and efficacy of deucravacitinib: An expert consensus panel. Dermatology Online Journal, 32(2). https://doi.org/10.25251/ymnfwz12
Vancouver
Shah M, DeBusk L, Bohman MH, Rosenberg A, Burshtein J, Zakria D, et al. A review of the indications, safety, and efficacy of deucravacitinib: An expert consensus panel. Dermatology Online Journal. 2026;32(2). doi:10.25251/ymnfwz12
BibTeX
@article{Shah2026,
author = {Shah, Milaan and DeBusk, Lauren and Bohman, M Hunter and Rosenberg, Angela and Burshtein, Joshua and Zakria, Danny and Armstrong, April and Boh, Erin and Gottlieb, Alice B and Khattri, Saakshi and Litchman, Graham and Merola, Joseph and Murina, Andrea and Lebwohl, Mark},
title = {A review of the indications, safety, and efficacy of deucravacitinib: An expert consensus panel},
journal = {Dermatology Online Journal},
year = {2026},
volume = {32},
number = {2},
doi = {10.25251/ymnfwz12}
}
EUVIMED